Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …

Background The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and
regulatory T (Treg) cells. The ability of selectively engaging either of these effects has …

Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …

The therapeutic potential of host-specific and tumour-specific immune responses is well
recognized and, after many years, active immunotherapies directed at inducing or …

During the past two decades, the paradigm for cancer treatment has evolved from relatively
nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer …

Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with
potential to provide greater clinical benefit to patients with advanced-stage cancer. In …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis.
However, their aberrant overexpression and glycosylation in various malignancies facilitate …

Importance The beneficial role of immunotherapy and the clinical relevance of current
biomarkers in non–small cell lung cancer (NSCLC) remain inconclusive; thus, appropriate …

More than many other fields in medicine, cancer vaccine development has been plagued by
a wide gap between the massive amounts of highly encouraging preclinical data on one …